Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 930 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cap Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Fed Bioavailability Study of Zonisamide Capsules

NCT00687167
View directory record Official record
Conditions
Healthy
Interventions
Zonisamide 100 mg Capsule, Zonisamide (Zonegran®) 100 mg Capsule
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2010 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Phase 2 Interventional Results available

CAP-Ketamine for Antidepressant Resistant PTSD

NCT02655692
View directory record Official record
Conditions
PTSD, Posttraumatic Stress Disorder
Interventions
Ketamine, Placebo/Saline
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
West Haven, Connecticut • Minneapolis, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating 3 New Formulations of SKI-606 in Healthy Adult Subjects

NCT00499538
View directory record Official record
Conditions
Healthy
Interventions
SKI-606
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Nitrofurantoin Macrocrystals 100 mg Capsules and Macrodantin® 100 mg

NCT00649506
View directory record Official record
Conditions
Healthy
Interventions
Nitrofurantoin Macrocrystals 100 mg Capsules, Macrodantin® 100 mg Capsules
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations

NCT01979484
View directory record Official record
Conditions
Pharmacokinetic Assessments in Healthy Volunteers
Interventions
PPI-668 capsule, PPI-668 tablet
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Phase 2 Interventional

Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

NCT05536414
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Centanafadine, Escitalopram, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
62
States / cities
Yuma, Arizona • Bryant, Arkansas • Glendale, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Phase 4 Interventional

A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules

NCT00281606
View directory record Official record
Conditions
HIV Infection
Interventions
Different formulations of once-daily lopinavir/ritonavir
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
5
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Phase 3 Interventional

A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients

NCT00002374
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Stavudine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Not applicable Interventional

Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

NCT01053559
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol
Drug
Lead sponsor
Shafran Gastroenterology Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study for Imaging of the Esophagus Using a Tethered Capsule OCT Endomicroscopy in the Primary Care Setting

NCT02445027
View directory record Official record
Conditions
Healthy
Interventions
MGH OCT Imaging Capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Atenolol 100mg Tablets Under Fasting Conditions

NCT00775580
View directory record Official record
Conditions
Healthy
Interventions
Atenolol 100mg Tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Chapell Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Oct 18, 2026, 1:17 PM EDT
Not listed Not applicable Interventional

Ingestion of Simethicone After Capsule Ingestion and Its Impact on Quality of Video Capsule Endoscopy- a Pilot Study

NCT03166605
View directory record Official record
Conditions
Video Capsule Endoscopy
Interventions
Simethicone
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 18, 2026, 1:17 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Transit Time and Bacterial Overgrowth Using SmartPill Capsule

NCT00577772
View directory record Official record
Conditions
Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases, Stomach Diseases, Digestive System Diseases
Interventions
Xifaxan, SmartPill, Lactulose hydrogen breath test (H_2BT)
Drug · Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to Water

NCT00768183
View directory record Official record
Conditions
Healthy
Interventions
KADIAN Capsule + alcohol (under fasting conditions), KADIAN Capsule + water (under fasting conditions), morphine sulfate IR oral solution + water, KADIAN Capsule + alcohol (under fed conditions)
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
21 Years to 40 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of SRX251 Capsules in Healthy Female Volunteers

NCT00461370
View directory record Official record
Conditions
Healthy
Interventions
SRX251
Drug
Lead sponsor
Azevan Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 13, 2008 · Synced Oct 18, 2026, 1:17 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule

NCT02202681
View directory record Official record
Conditions
Celiac Disease, Healthy
Interventions
OFDI Capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease

NCT01045096
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Year to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Anaheim, California • Miami Garden, Florida • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

NCT01761773
View directory record Official record
Conditions
Healthy, Renal Impairment
Interventions
cabozantinib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

NCT02633527
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Placebo, 100mg SPN-812, 200mg SPN-812, 300mg SPN-812, 400mg SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Maitland, Florida
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

NCT01428583
View directory record Official record
Conditions
Chronic Noncancer Pain
Interventions
oxycodone HCl and naltrexone HCl extended-release capsules
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
32
States / cities
DeLand, Florida • Jacksonville, Florida • Jupiter, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 18, 2026, 1:17 PM EDT
Completed No phase listed Observational

OCS Liver PROTECT Continued Access Protocol (CAP) Continuation Post-Approval Study

NCT05096754
View directory record Official record
Conditions
Liver Transplant
Interventions
OCS Liver
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
11
States / cities
La Jolla, California • San Francisco, California • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

NCT03562156
View directory record Official record
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
Oteseconazole (VT-1161), Placebo
Drug
Lead sponsor
Mycovia Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
25
States / cities
Birmingham, Alabama • San Diego, California • Lauderdale Lakes, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 18, 2026, 1:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess New Formulations of TEV-56286

NCT06911567
View directory record Official record
Conditions
Healthy Participants
Interventions
TEV-56286 Test, TEV-56286 Reference
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 18, 2026, 1:17 PM EDT
Active, not recruiting Not applicable Interventional

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

NCT05370469
View directory record Official record
Conditions
Lung Cancer, EGFR Gene Mutation, EGFR, ALK Gene Mutation, RET Gene Mutation, MET Gene Mutation, KRAS Mutation-Related Tumors, BRAF, ROS1 Gene Mutation
Interventions
Sensus Smartwatch Application, RX Cap, Fitbit Sense, Surveys
Other · Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 18, 2026, 1:17 PM EDT